synergy with SGLT2 inhibitors
Methylene blue supports energy by improving mitochondrial function, helping cells produce and use energy more efficiently instead of stimulating the nervous system like caffeine
This means it happened in a small number of patients during studies, and may continue to happen in real-world use
State Medicaid programs will also have access to these medications at these prices. CNBC reported on November 6, 2025, that Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more private insurers to cover them. A senior administration official explained the rationale to CNBC: We are constraining the access for patients that will benefit clinically from it, weve worked very hard to strike a balance between broad access that just makes sure to capture patients that will benefit clinically. Documentation of these qualifying conditions will be essential for coverage approval
CGM as a behavior change tool CGM helps make the invisible, visible
TengLYLeeVWMurugesuSLeeJXIbrahimNSIshakMFet al